PERIPHERAL T-CELL LYMPHOMA
Clinical trials for PERIPHERAL T-CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new PERIPHERAL T-CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for PERIPHERAL T-CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Can a cancer drug boost stem cell transplants for rare T-Cell cancers?
Disease control CompletedThis early-phase study tested adding the drug romidepsin to standard chemotherapy before and after a stem cell transplant in 23 people with certain T-cell cancers. The goal was to find a safe dose and see if the combination could help control the cancer. Participants received the…
Matched conditions: PERIPHERAL T-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Disease control
Last updated May 26, 2026 04:36 UTC
-
New combo therapy for lymphoma shows promise in early trial
Disease control CompletedThis early-phase study tested a new combination of drugs (romidepsin plus standard chemotherapy) in 21 patients with two types of lymphoma. The main goal was to find the safest dose and understand side effects. Researchers hope this approach could lead to better outcomes, but mor…
Matched conditions: PERIPHERAL T-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: Canadian Cancer Trials Group • Aim: Disease control
Last updated May 26, 2026 04:35 UTC
-
Immunotherapy after transplant shows promise for tough lymphomas
Disease control CompletedThis study tested whether giving the immunotherapy drug pembrolizumab after a stem cell transplant can help keep lymphoma from coming back. It included 82 people with Hodgkin lymphoma, diffuse large B-cell lymphoma, or T-cell lymphoma that had returned or not responded to prior t…
Matched conditions: PERIPHERAL T-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated May 26, 2026 04:33 UTC
-
New combo therapy shows promise for Hard-to-Treat lymphoma
Disease control CompletedThis study tested a combination of two drugs, nivolumab and cabiralizumab, in 4 adults with a rare and aggressive blood cancer called peripheral T-cell lymphoma that had come back or not responded to prior treatments. The goal was to see if the combination could shrink tumors. Th…
Matched conditions: PERIPHERAL T-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: University of Michigan Rogel Cancer Center • Aim: Disease control
Last updated May 26, 2026 04:33 UTC
-
New drug shows promise for Hard-to-Treat cancers with p53 gene
Disease control CompletedThis early-stage study tested a drug called ALRN-6924 in 142 people with advanced solid tumors or lymphomas that have a normal p53 gene. The main goals were to check safety and find the best dose. Researchers also looked for signs that the drug could shrink tumors. The study is n…
Matched conditions: PERIPHERAL T-CELL LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Aileron Therapeutics, Inc. • Aim: Disease control
Last updated May 26, 2026 04:30 UTC
-
New drug candidate BR101801 tested in patients with advanced blood cancers
Disease control CompletedThis early-phase trial tested a new drug called BR101801 in 26 adults with advanced blood cancers like lymphoma and leukemia that had not responded to other treatments. The main goals were to find a safe dose and check for side effects. The study was completed, but results are no…
Matched conditions: PERIPHERAL T-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: Boryung Pharmaceutical Co., Ltd • Aim: Disease control
Last updated May 26, 2026 04:25 UTC
-
New drug cocktail shows promise for Hard-to-Treat blood cancers
Disease control CompletedThis early-phase study tested a combination of four drugs (romidepsin, CC-486, dexamethasone, and lenalidomide) in 26 adults with T-cell cancers that had come back or stopped responding to standard treatments. The main goal was to find a safe dose and check for side effects. Rese…
Matched conditions: PERIPHERAL T-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 03:58 UTC
-
New pill shows promise against hard-to-treat lymphoma
Disease control CompletedThis study tested an oral drug called AZD4205 in 57 adults with peripheral T-cell lymphoma that returned or didn't respond to at least one prior therapy. The goal was to see if the drug could shrink tumors and how safe it was. Participants took one pill daily, and researchers mea…
Matched conditions: PERIPHERAL T-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Dizal Pharmaceuticals • Aim: Disease control
Last updated May 22, 2026 13:53 UTC
-
New combo shows promise for hard-to-treat lymphoma
Disease control CompletedThis study tested a drug called brentuximab vedotin combined with standard chemotherapy (CHP) in 82 people with a rare type of blood cancer called peripheral T-cell lymphoma (PTCL) that has low levels of a protein called CD30. The goal was to see if the combination helps shrink o…
Matched conditions: PERIPHERAL T-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Seagen, a wholly owned subsidiary of Pfizer • Aim: Disease control
Last updated May 18, 2026 12:03 UTC